Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596453 · ClinicalTrials.gov registry record · Phase 4
Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
A Phase 4 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00596453: Clinical Trial Phase 4 study, sponsored by Johns Hopkins University.
NCT00596453 is a Phase 4 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596453, a Phase 4 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused by inflammation or swelling of the prostate. Antibiotics are used to treat such inflammatory conditions. However, it has not been proven that antibiotics can be used to lower PSA. This research is being done to see if treatment with the antibiotic Ciprofloxacin hydrochloride affects the Prostate-Specific Antigen (PSA) blood test. This study may also help doctors in deciding which patients need a prostate biopsy.
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596453
The ClinicalTrials.gov registry entry for NCT00596453 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00596453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00596453 about?
NCT00596453 is a clinical study titled "Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability". Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused ...
What is the current status of trial NCT00596453?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2008-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00596453?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00596453?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.